Through our participation in the Microphysiological Systems (MPS) initiative, abc biopply becomes part of a dynamic international network committed to fostering industry-wide collaboration. The initiative aims to accelerate the adoption and regulatory acceptance of next-generation technologies that refine, reduce, and ultimately replace the use of animals in research. These approaches not only support more ethical drug discovery and development, but also offer the potential for more predictive, human-relevant outcomes.

As Europe’s first fully integrated organoid CRO, we are proud to contribute our next-generation humanized multi-organoid models and New Approach Methodologies (NAMs) to this global effort. Our technologies are designed to deliver standardized, validated, and more predictive results across a broad range of therapeutic areas, including oncology, neurology, hepatology, metabolic diseases, and beyond.

By supporting the MPS initiative with robust, human-relevant models, we aim to help close the translational gap, significantly reduce reliance on animal testing, and accelerate drug discovery and development.
[biopply.com]

We firmly believe that the future of science depends on smarter, more responsible innovation—and we’re proud to be part of that transformation.

Let’s build a better future for science—together.